mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment.

[1]  Jacqunae Mays,et al.  Targeted suppression of mTORC2 reduces seizures across models of epilepsy , 2023, Nature communications.

[2]  Lucas E. Flausino,et al.  Neuroinflammation: An astrocyte perspective , 2023, Science Translational Medicine.

[3]  M. Brodie,et al.  Editorial: Epidemiology of epilepsy and seizures , 2023, Frontiers in epidemiology.

[4]  A. Orsini,et al.  The Influence of Ketogenic Diet on Gut Microbiota: Potential Benefits, Risks and Indications , 2023, Nutrients.

[5]  Yuanyuan Yao,et al.  Microglia sense and suppress epileptic neuronal hyperexcitability. , 2023, Pharmacological research.

[6]  D. Schubert,et al.  Excitatory/inhibitory balance in epilepsies and neurodevelopmental disorders: Depolarizing γ‐aminobutyric acid as a common mechanism , 2023, Epilepsia.

[7]  S. Baulac,et al.  mTOR pathway: Insights into an established pathway for brain mosaicism in epilepsy , 2023, Neurobiology of Disease.

[8]  K. Kotulska,et al.  Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age , 2023, Neurology and Therapy.

[9]  H. Shiraishi,et al.  Efficacy of sirolimus for epileptic seizures in childhood associated with focal cortical dysplasia type II , 2023, Brain and Development.

[10]  E. Aronica,et al.  Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy , 2023, Brain : a journal of neurology.

[11]  A. Vezzani,et al.  Neuroimmunology of status epilepticus , 2023, Epilepsy & Behavior.

[12]  A. Vezzani,et al.  Neuroinflammation microenvironment sharpens seizure circuit , 2023, Neurobiology of Disease.

[13]  M. de Curtis,et al.  Dendritic spine loss in epileptogenic Type II focal cortical dysplasia: Role of enhanced classical complement pathway activation , 2022, Brain pathology.

[14]  J. D. Mills,et al.  GABAA receptor function is enhanced by Interleukin-10 in human epileptogenic gangliogliomas and its effect is counteracted by Interleukin-1β , 2022, Scientific Reports.

[15]  E. Aronica,et al.  Astrocytes in the initiation and progression of epilepsy , 2022, Nature Reviews Neurology.

[16]  L. Foley,et al.  Microglial–oligodendrocyte interactions in myelination and neurological function recovery after traumatic brain injury , 2022, Journal of Neuroinflammation.

[17]  J. Bateman,et al.  Mechanistic target of rapamycin signaling in human nervous system development and disease , 2022, Frontiers in Molecular Neuroscience.

[18]  Dunfang Zhang,et al.  Excessive intake of sugar: An accomplice of inflammation , 2022, Frontiers in Immunology.

[19]  C. Elger,et al.  ‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy , 2022, Brain : a journal of neurology.

[20]  S. Schoch,et al.  Characterisation of NLRP3 pathway-related neuroinflammation in temporal lobe epilepsy , 2022, PloS one.

[21]  M. Fujimoto,et al.  Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice , 2022, Neuropharmacology.

[22]  Fenghua Chen,et al.  The Coordination of mTOR Signaling and Non-Coding RNA in Regulating Epileptic Neuroinflammation , 2022, Frontiers in Immunology.

[23]  C. Lei,et al.  HMGB1/TLR4 induces autophagy and promotes neuroinflammation after intracerebral hemorrhage , 2022, Brain Research.

[24]  F. Ginhoux,et al.  Single-cell transcriptomics and surface epitope detection in human brain epileptic lesions identifies pro-inflammatory signaling , 2022, Nature neuroscience.

[25]  F. Cendes,et al.  The ILAE consensus classification of focal cortical dysplasia: An update proposed by an ad hoc task force of the ILAE diagnostic methods commission , 2022, Epilepsia.

[26]  B. Ueberheide,et al.  Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia , 2022, PloS one.

[27]  D. Kaufer,et al.  Blood–brain barrier dysfunction promotes astrocyte senescence through albumin‐induced TGFβ signaling activation , 2022, bioRxiv.

[28]  A. Bordey,et al.  Current Review in Basic Science: Animal Models of Focal Cortical Dysplasia and Epilepsy , 2022, Epilepsy currents.

[29]  J. Rho,et al.  The metabolic basis of epilepsy , 2022, Nature Reviews Neurology.

[30]  F. Yousefi,et al.  Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain injury: A novel insight into targeted therapy , 2022, Cell biochemistry and function.

[31]  Hui Yang,et al.  Glucocorticoid receptors participate in epilepsy in FCDII patients and MP model rats: A potential therapeutic target for epilepsy in patients with focal cortical dysplasia II (FCDII) , 2022, Expert opinion on therapeutic targets.

[32]  Mercedes F. Paredes,et al.  Amplification of human interneuron progenitors promotes brain tumors and neurological defects , 2022, Science.

[33]  A. Kakita,et al.  Sirolimus for epileptic seizures associated with focal cortical dysplasia type II , 2022, Annals of clinical and translational neurology.

[34]  D. Rotaru,et al.  Identifying the temporal electrophysiological and molecular changes that contribute to TSC-associated epileptogenesis , 2021, JCI insight.

[35]  Xiaoming Jin,et al.  Blocking receptor for advanced glycation end products (RAGE) or toll‐like receptor 4 (TLR4) prevents posttraumatic epileptogenesis in mice , 2021, Epilepsia.

[36]  S. Fernandes,et al.  The Multifaceted Role of Nutrient Sensing and mTORC1 Signaling in Physiology and Aging , 2021, Frontiers in Aging.

[37]  L. Concha,et al.  A systems‐level analysis highlights microglial activation as a modifying factor in common epilepsies , 2021, Neuropathology and applied neurobiology.

[38]  S. Cuzzocrea,et al.  The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury , 2021, Journal of cellular and molecular medicine.

[39]  W. Löscher,et al.  New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal? , 2021, Pharmacology & therapeutics.

[40]  E. Aronica,et al.  Impaired myelin production due to an intrinsic failure of oligodendrocytes in mTORpathies , 2021, Neuropathology and applied neurobiology.

[41]  S. Cavalheiro,et al.  Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report , 2021, Child's Nervous System.

[42]  J. D. Mills,et al.  Balloon cells promote immune system activation in focal cortical dysplasia type 2b , 2021, Neuropathology and applied neurobiology.

[43]  R. D’Ambrosio,et al.  Antiepileptogenesis and disease modification: Progress, challenges, and the path forward—Report of the Preclinical Working Group of the 2018 NINDS‐sponsored antiepileptogenesis and disease modification workshop , 2021, Epilepsia open.

[44]  A. Bordey,et al.  Convergent and Divergent Mechanisms of Epileptogenesis in mTORopathies , 2021, Frontiers in Neuroanatomy.

[45]  P. Jat,et al.  Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype , 2021, Frontiers in Cell and Developmental Biology.

[46]  E. Suleymanova.  Behavioral comorbidities of epilepsy and neuroinflammation: Evidence from experimental and clinical studies , 2021, Epilepsy & Behavior.

[47]  D. Kaping,et al.  mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus , 2021, Journal of neurodevelopmental disorders.

[48]  M. de Curtis,et al.  A hypothesis for the role of axon demyelination in seizure generation , 2021, Epilepsia.

[49]  E. Aronica,et al.  Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway , 2021, Epilepsy & Behavior.

[50]  P. Kwan,et al.  Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease , 2020, Epilepsia.

[51]  S. Danzer,et al.  mTOR-driven neural circuit changes initiate an epileptogenic cascade , 2020, Progress in Neurobiology.

[52]  S. Rosi,et al.  Microglia depletion and cognitive functions after brain injury: From trauma to galactic cosmic ray , 2020, Neuroscience Letters.

[53]  D. Spencer,et al.  Ectopic HCN4 expression drives mTOR-dependent epilepsy in mice , 2020, Science Translational Medicine.

[54]  B. Trapp,et al.  Microglial Displacement of GABAergic Synapses Is a Protective Event during Complex Febrile Seizures. , 2020, Cell reports.

[55]  K. Shokat,et al.  Brain-restricted mTOR inhibition with binary pharmacology , 2020, bioRxiv.

[56]  E. Aronica,et al.  Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy During Epileptogenesis , 2020, Frontiers in Neurology.

[57]  J. D. Mills,et al.  Myelin Pathology Beyond White Matter in Tuberous Sclerosis Complex (TSC) Cortical Tubers , 2020, Journal of neuropathology and experimental neurology.

[58]  Ukpong B. Eyo,et al.  Negative feedback control of neuronal activity by microglia , 2020, Nature.

[59]  A. Represa,et al.  Progression of Fetal Brain Lesions in Tuberous Sclerosis Complex , 2020, Frontiers in Neuroscience.

[60]  D. Henshall,et al.  MicroRNAs as regulators of brain function and targets for treatment of epilepsy , 2020, Nature Reviews Neurology.

[61]  W. Löscher,et al.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options , 2020, Pharmacological Reviews.

[62]  L. Lagae,et al.  Ketogenic diet for the treatment of pediatric epilepsy: review and meta-analysis , 2020, Child's Nervous System.

[63]  F. Biagioni,et al.  mTOR-Related Cell-Clearing Systems in Epileptic Seizures, an Update , 2020, International journal of molecular sciences.

[64]  J. D. Mills,et al.  Coding and non-coding transcriptome of mesial temporal lobe epilepsy: Critical role of small non-coding RNAs , 2020, Neurobiology of Disease.

[65]  D. Reutens,et al.  Complement in the development of post-traumatic epilepsy: prospects for drug repurposing. , 2020, Journal of neurotrauma.

[66]  J. Lugo,et al.  Therapeutic role of targeting mTOR signaling and neuroinflammation in epilepsy , 2020, Epilepsy Research.

[67]  Xing-jie Liang,et al.  Lipopolysaccharide induces neuroinflammation in microglia by activating the MTOR pathway and downregulating Vps34 to inhibit autophagosome formation , 2020, Journal of Neuroinflammation.

[68]  W. Löscher,et al.  Structural, Molecular, and Functional Alterations of the Blood-Brain Barrier during Epileptogenesis and Epilepsy: A Cause, Consequence, or Both? , 2020, International journal of molecular sciences.

[69]  A. Kulkarni,et al.  Differential regulation of autophagy during metabolic stress in astrocytes and neurons , 2019, Autophagy.

[70]  J. D. Mills,et al.  Chronic activation of anti‐oxidant pathways and iron accumulation in epileptogenic malformations , 2019, Neuropathology and applied neurobiology.

[71]  S. Duan,et al.  mTOR‐mediated metabolic reprogramming shapes distinct microglia functions in response to lipopolysaccharide and ATP , 2019, Glia.

[72]  A. Zamani,et al.  Neuroinflammation in Post-Traumatic Epilepsy: Pathophysiology and Tractable Therapeutic Targets , 2019, Brain sciences.

[73]  P. Crino,et al.  GATORopathies: The role of amino acid regulatory gene mutations in epilepsy and cortical malformations , 2019, Epilepsia.

[74]  W. Löscher.  Consequences of housing conditions and interindividual diversity in rodent models of acquired epilepsy , 2019, Epilepsia.

[75]  E. Aronica,et al.  New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives , 2019, Journal of anatomy.

[76]  M. Yousefi,et al.  mTOR Signaling pathway as a master regulator of memory CD8+ T‐cells, Th17, and NK cells development and their functional properties , 2019, Journal of cellular physiology.

[77]  P. V. van Rijen,et al.  Increased matrix metalloproteinases expression in tuberous sclerosis complex: modulation by microRNA 146a and 147b in vitro , 2019, Neuropathology and Applied Neurobiology.

[78]  A. Vezzani,et al.  Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy , 2019, Nature Reviews Neurology.

[79]  Y. Elgersma,et al.  Effects of antiepileptic drugs in a new TSC/mTOR‐dependent epilepsy mouse model , 2019, Annals of clinical and translational neurology.

[80]  A. Ziegler,et al.  Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study , 2019, Orphanet Journal of Rare Diseases.

[81]  E. Aronica,et al.  The Roof is Leaking and a Storm is Raging: Repairing the Blood–Brain Barrier in the Fight Against Epilepsy , 2019, Epilepsy currents.

[82]  C. Howe,et al.  Functional deficiency in endogenous interleukin‐1 receptor antagonist in patients with febrile infection‐related epilepsy syndrome , 2019, Annals of neurology.

[83]  C. Torres,et al.  Astrocyte senescence: Evidence and significance , 2019, Aging cell.

[84]  Dipan C. Patel,et al.  Neuron–glia interactions in the pathophysiology of epilepsy , 2019, Nature Reviews Neuroscience.

[85]  N. Toni,et al.  Astrocyte function from information processing to cognition and cognitive impairment , 2019, Nature Neuroscience.

[86]  K. Kapur,et al.  Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex. , 2019, Pediatric neurology.

[87]  R. Dingledine,et al.  The COX-2/prostanoid signaling cascades in seizure disorders , 2018, Expert opinion on therapeutic targets.

[88]  J. D. Mills,et al.  Oxidative stress and inflammation in a spectrum of epileptogenic cortical malformations: molecular insights into their interdependence , 2018, Brain pathology.

[89]  C. Mao,et al.  A Critical Role of Autophagy in Regulating Microglia Polarization in Neurodegeneration , 2018, Front. Aging Neurosci..

[90]  O. Devinsky,et al.  Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. , 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[91]  J. C. Baayen,et al.  Activation of the innate immune system is evident throughout epileptogenesis and is associated with blood‐brain barrier dysfunction and seizure progression , 2018, Epilepsia.

[92]  B. Zhang,et al.  The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex , 2018, Epilepsia.

[93]  E. Aronica,et al.  Effects of rapamycin and curcumin on inflammation and oxidative stress in vitro and in vivo — in search of potential anti-epileptogenic strategies for temporal lobe epilepsy , 2018, Journal of Neuroinflammation.

[94]  I. Scheffer,et al.  Epilepsy , 2018, Nature Reviews Disease Primers.

[95]  R. Garbelli,et al.  Seizure progression and inflammatory mediators promote pericytosis and pericyte-microglia clustering at the cerebrovasculature , 2018, Neurobiology of Disease.

[96]  Z. Ungvari,et al.  Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment. , 2018, American journal of physiology. Heart and circulatory physiology.

[97]  Julia W. Chang,et al.  Noninflammatory Changes of Microglia Are Sufficient to Cause Epilepsy , 2018, Cell reports.

[98]  E. Aronica,et al.  Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies , 2018, Neuropathology and applied neurobiology.

[99]  T. Lucas,et al.  Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy , 2018, Annals of neurology.

[100]  E. Aronica,et al.  mTOR dysregulation and tuberous sclerosis-related epilepsy , 2018, Expert review of neurotherapeutics.

[101]  A. Vezzani,et al.  Inhibition of monoacylglycerol lipase terminates diazepam‐resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet , 2018, Epilepsia.

[102]  R. Dingledine,et al.  Commonalities in epileptogenic processes from different acute brain insults: Do they translate? , 2018, Epilepsia.

[103]  U. Suter,et al.  Myelination and mTOR , 2017, Glia.

[104]  A. Vezzani,et al.  High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy , 2017, Brain, Behavior, and Immunity.

[105]  J. D. Mills,et al.  Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment , 2017, Scientific Reports.

[106]  D. Prince,et al.  TGFβ signaling is associated with changes in inflammatory gene expression and perineuronal net degradation around inhibitory neurons following various neurological insults , 2017, Scientific Reports.

[107]  J. C. Baayen,et al.  Increased expression of (immuno)proteasome subunits during epileptogenesis is attenuated by inhibition of the mammalian target of rapamycin pathway , 2017, Epilepsia.

[108]  S. Brun,et al.  Autophagy in neuroinflammatory diseases. , 2017, Autoimmunity reviews.

[109]  W. Löscher,et al.  Neuroinflammatory targets and treatments for epilepsy validated in experimental models , 2017, Epilepsia.

[110]  D. Reddy,et al.  Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[111]  D. Kaufer,et al.  Imaging blood–brain barrier dysfunction as a biomarker for epileptogenesis , 2017, Brain : a journal of neurology.

[112]  Shumei S. Sun,et al.  Plasma cytokines associated with febrile status epilepticus in children: A potential biomarker for acute hippocampal injury , 2017, Epilepsia.

[113]  F. Yin,et al.  Interleukin-1β Plays a Pivotal Role via the PI3K/Akt/mTOR Signaling Pathway in the Chronicity of Mesial Temporal Lobe Epilepsy , 2017, Neuroimmunomodulation.

[114]  J. Rho,et al.  Ketone Bodies as Anti-Seizure Agents , 2017, Neurochemical Research.

[115]  Edouard Hirsch,et al.  ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology , 2017, Epilepsia.

[116]  David M. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[117]  M. Zucchetti,et al.  Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy , 2017, Neurobiology of Disease.

[118]  J. Jaworski,et al.  Molecular neurobiology of mTOR , 2017, Neuroscience.

[119]  Ukpong B. Eyo,et al.  Microglia–Neuron Communication in Epilepsy , 2017, Glia.

[120]  C. Limatola,et al.  Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions , 2016, Neurobiology of Disease.

[121]  Changjuan Wei,et al.  Everolimus (RAD001) ameliorates vascular cognitive impairment by regulating microglial function via the mTORC1 signaling pathway , 2016, Journal of Neuroimmunology.

[122]  S. Barnett,et al.  The multifaceted role of astrocytes in regulating myelination , 2016, Experimental Neurology.

[123]  P. V. van Rijen,et al.  Dysregulation of the (immuno)proteasome pathway in malformations of cortical development , 2016, Journal of Neuroinflammation.

[124]  B. Zhang,et al.  Microglial activation during epileptogenesis in a mouse model of tuberous sclerosis complex , 2016, Epilepsia.

[125]  E. Aronica,et al.  Expression of microRNAs miR21, miR146a, and miR155 in tuberous sclerosis complex cortical tubers and their regulation in human astrocytes and SEGA‐derived cell cultures , 2016, Glia.

[126]  E. Aronica,et al.  Promoter-Specific Hypomethylation Correlates with IL-1β Overexpression in Tuberous Sclerosis Complex (TSC) , 2016, Journal of Molecular Neuroscience.

[127]  W. Guo,et al.  Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex , 2016, Journal of Neuroinflammation.

[128]  E. Aronica,et al.  Immunity and Inflammation in Epilepsy. , 2016, Cold Spring Harbor perspectives in medicine.

[129]  E. Aronica,et al.  Blood–brain barrier leakage after status epilepticus in rapamycin‐treated rats II: Potential mechanisms , 2016, Epilepsia.

[130]  E. Aronica,et al.  Blood–brain barrier leakage after status epilepticus in rapamycin‐treated rats I: Magnetic resonance imaging , 2016, Epilepsia.

[131]  P. Kloetzel,et al.  The immunoproteasome β5i subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy , 2015, Brain, Behavior, and Immunity.

[132]  C. Limatola,et al.  GABAA currents are decreased by IL-1β in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis , 2015, Neurobiology of Disease.

[133]  P. Marin,et al.  mTOR in Brain Physiology and Pathologies. , 2015, Physiological reviews.

[134]  Kosuke Tomimatsu,et al.  Translating the effects of mTOR on secretory senescence , 2015, Nature Cell Biology.

[135]  T. Weichhart,et al.  Regulation of innate immune cell function by mTOR , 2015, Nature Reviews Immunology.

[136]  A. Vezzani,et al.  Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability , 2015, Neuropharmacology.

[137]  N. Rensing,et al.  Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex , 2015, Neurobiology of Disease.

[138]  J. Rubenstein,et al.  The parvalbumin/somatostatin ratio is increased in Pten mutant mice and by human PTEN ASD alleles. , 2015, Cell reports.

[139]  J. Schramm,et al.  Astrocyte uncoupling as a cause of human temporal lobe epilepsy. , 2015, Brain : a journal of neurology.

[140]  Seok-Gu Kang,et al.  Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy , 2015, Nature Medicine.

[141]  E. Aronica,et al.  Blood-brain barrier dysfunction, seizures and epilepsy. , 2015, Seminars in cell & developmental biology.

[142]  R. Dingledine,et al.  Candidate drug targets for prevention or modification of epilepsy. , 2015, Annual review of pharmacology and toxicology.

[143]  M. Bianchi,et al.  Disulfide-containing high mobility group box-1 promotes N-methyl-D-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal neurons. , 2014, Antioxidants & redox signaling.

[144]  Y. Ben-Ari,et al.  Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model , 2014, Nature Communications.

[145]  A. Coppola,et al.  Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies , 2014, Acta neuropathologica communications.

[146]  U. Heinemann,et al.  Losartan prevents acquired epilepsy via TGF‐β signaling suppression , 2014, Annals of neurology.

[147]  Seyedeh-Atiyeh Afjei,et al.  Brain inflammation induces post-synaptic changes during early synapse formation in adult-born hippocampal neurons , 2013, Experimental Neurology.

[148]  J. Sandkühler,et al.  Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity , 2013, Nature Reviews Neuroscience.

[149]  S. Cichon,et al.  TLR4, ATF-3 and IL8 inflammation mediator expression correlates with seizure frequency in human epileptic brain tissue , 2013, Seizure.

[150]  Aaron J. Johnson,et al.  Theiler’s murine encephalomyelitis virus as an experimental model system to study the mechanism of blood–brain barrier disruption , 2013, Journal of NeuroVirology.

[151]  E. Powell.  Interneuron Development and Epilepsy: Early Genetic Defects Cause Long-Term Consequences in Seizures and Susceptibility , 2013, Epilepsy currents.

[152]  W. Harkness,et al.  mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis , 2013, Acta Neuropathologica.

[153]  D. Brody,et al.  Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury , 2013, PloS one.

[154]  Bernardo L. Sabatini,et al.  Excitatory/Inhibitory Synaptic Imbalance Leads to Hippocampal Hyperexcitability in Mouse Models of Tuberous Sclerosis , 2013, Neuron.

[155]  Ben A. Barres,et al.  Emerging roles of astrocytes in neural circuit development , 2013, Nature Reviews Neuroscience.

[156]  A. Anderson,et al.  Rapamycin Reverses Status Epilepticus-Induced Memory Deficits and Dendritic Damage , 2013, PloS one.

[157]  D. Feinstein,et al.  mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis , 2013, Glia.

[158]  M. Wong.  Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases , 2013, Biomedical journal.

[159]  R. Sankar,et al.  Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain , 2013, Journal of Neuroinflammation.

[160]  P. Crino,et al.  The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy , 2013, Front. Neur..

[161]  E. Aronica,et al.  Fetal Brain Lesions in Tuberous Sclerosis Complex: TORC1 Activation and Inflammation , 2013, Brain pathology.

[162]  A. Vezzani,et al.  Long‐lasting pro‐ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology , 2012, Epilepsia.

[163]  A. A. Kan,et al.  Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines , 2012, Journal of Neuroinflammation.

[164]  E. Nagelhus,et al.  Aquaporin‐4 and epilepsy , 2012, Glia.

[165]  Jan A Gorter,et al.  Finding a better drug for epilepsy: The mTOR pathway as an antiepileptogenic target , 2012, Epilepsia.

[166]  Charles B. Mikell,et al.  The mTOR pathway is activated in glial cells in mesial temporal sclerosis , 2012, Epilepsia.

[167]  K. Lukasiuk,et al.  Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy , 2012, Neuroscience Letters.

[168]  Q. Pittman,et al.  Cytokines and brain excitability , 2012, Frontiers in Neuroendocrinology.

[169]  A. Vezzani,et al.  IL-1β is induced in reactive astrocytes in the somatosensory cortex of rats with genetic absence epilepsy at the onset of spike-and-wave discharges, and contributes to their occurrence , 2011, Neurobiology of Disease.

[170]  T. Bártfai,et al.  IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures , 2011, Brain, Behavior, and Immunity.

[171]  P. V. van Rijen,et al.  Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. , 2011, Brain : a journal of neurology.

[172]  Kelvin A. Yamada,et al.  The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway , 2011, Epilepsia.

[173]  D. Feinstein,et al.  The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes , 2011, Journal of Neuroinflammation.

[174]  Yunfei Huang,et al.  Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy , 2010, Neurobiology of Disease.

[175]  P. V. van Rijen,et al.  Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias , 2010, Epilepsia.

[176]  L. Zeng,et al.  Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): A double-edged sword? , 2010, Cell cycle.

[177]  A. McAllister,et al.  Novel Roles for Immune Molecules in Neural Development: Implications for Neurodevelopmental Disorders , 2010, Front. Syn. Neurosci..

[178]  E. Aronica,et al.  Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures , 2010, Nature Medicine.

[179]  T. Kilpatrick,et al.  Role of Cytokines as Mediators and Regulators of Microglial Activity in Inflammatory Demyelination of the CNS , 2010, NeuroMolecular Medicine.

[180]  T. McMorrow,et al.  Sirolimus and cyclosporine A alter barrier function in renal proximal tubular cells through stimulation of ERK1/2 signaling and claudin-1 expression. , 2010, American journal of physiology. Renal physiology.

[181]  M. Wainwright,et al.  Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways , 2010, Brain Research.

[182]  P. V. van Rijen,et al.  Gene Expression Analysis of Tuberous Sclerosis Complex Cortical Tubers Reveals Increased Expression of Adhesion and Inflammatory Factors , 2009, Brain pathology.

[183]  H. Scharfman,et al.  Postnatal neurogenesis as a therapeutic target in temporal lobe epilepsy , 2009, Epilepsy Research.

[184]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[185]  C. Stafstrom,et al.  Anticonvulsant and antiepileptic actions of 2‐deoxy‐D‐glucose in epilepsy models , 2009, Annals of neurology.

[186]  T. Bártfai,et al.  A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. , 2008, Brain : a journal of neurology.

[187]  D. Gutmann,et al.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex , 2008, Annals of neurology.

[188]  L. Kaczmarek,et al.  Important role of matrix metalloproteinase 9 in epileptogenesis , 2008, The Journal of cell biology.

[189]  Charles B. Mikell,et al.  Tuberous sclerosis: A primary pathology of astrocytes? , 2008, Epilepsia.

[190]  E. Aronica,et al.  Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex , 2008, Epilepsy Research.

[191]  Eleonora Aronica,et al.  Innate and adaptive immunity during epileptogenesis and spontaneous seizures: Evidence from experimental models and human temporal lobe epilepsy , 2008, Neurobiology of Disease.

[192]  John D. Lambris,et al.  The Classical Complement Cascade Mediates CNS Synapse Elimination , 2007, Cell.

[193]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[194]  F. L. D. Silva,et al.  Complement activation in experimental and human temporal lobe epilepsy , 2007, Neurobiology of Disease.

[195]  Y. Jan,et al.  Activity- and mTOR-Dependent Suppression of Kv1.1 Channel mRNA Translation in Dendrites , 2006, Science.

[196]  E. Aronica,et al.  The IL-1β system in epilepsy-associated malformations of cortical development , 2006, Neurobiology of Disease.

[197]  P. Crino,et al.  Epileptogenesis and Reduced Inward Rectifier Potassium Current in Tuberous Sclerosis Complex‐1–Deficient Astrocytes , 2005, Epilepsia.

[198]  Tallie Z. Baram,et al.  The role of inflammation in epilepsy , 2011, Nature Reviews Neurology.